Skip to main content
Top
Published in: Pituitary 4/2009

01-12-2009

Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique

Authors: Alpaslan Tuzcu, Serkan Yalaki, Senay Arikan, Deniz Gokalp, Mithat Bahcec, Sadiye Tuzcu

Published in: Pituitary | Issue 4/2009

Login to get access

Abstract

The background and aim of the study is to evaluate insulin sensitivity in hyperprolactinemic subjects via euglycemic hyperinsulinemic clamp technique. Sixteen hyperprolactinemic subjects and 12 healthy subjects were included in the study. HOMA-B and HOMA-IR values of groups were calculated. Euglycemic hyperinsulinemic clamp technique was performed in both groups, and the M value of the groups was defined. Mann–Whitney U and chi-square tests were used in statistical analysis. Basal insulin level of hyperprolactinemic patients were higher than the control group (6.85 ± 4.68; 3.66 ± 0.88 μU/ml respectively; P < 0.05). Mean HOMA-IR and HOMA-B values of patients were higher than control group (1.49 ± 1.30; 0.78 ± 0.27 respectively; P = 0.02 and 136.28 ± 72.53; 64.77 ± 23.31, respectively, P < 0.001). M values of the patients were statistically lower than the control group (5.64 ± 2.36; 7.05 ± 1.62 kg/mg/min respectively; P < 0.05). (1) Hyperprolactinemic patients were more insulin resistant than control subjects. (2) Insulin resistance in hyperprolactinemic patients is not associated with obesity or anthropometric parameters such as fat content, waist circumference and BMI.
Literature
1.
go back to reference Baptista T et al (2004) Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Prog Neuropsychopharmacol Biol Psychiatry 28:1305–1311. doi:10.1016/j.pnpbp.2004.08.001 CrossRefPubMed Baptista T et al (2004) Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Prog Neuropsychopharmacol Biol Psychiatry 28:1305–1311. doi:10.​1016/​j.​pnpbp.​2004.​08.​001 CrossRefPubMed
2.
go back to reference Knudtzon J, Johansen PW, Haug E, Gautvik K (1986) Effects of hypersecretion of growth hormone and prolactin on plasma levels of glucagon and insulin in GH3-celltumor-bearing rats, and the influence of bromocriptine treatment. Life Sci 39:617–621. doi:10.1016/0024-3205(86)90042-1 CrossRefPubMed Knudtzon J, Johansen PW, Haug E, Gautvik K (1986) Effects of hypersecretion of growth hormone and prolactin on plasma levels of glucagon and insulin in GH3-celltumor-bearing rats, and the influence of bromocriptine treatment. Life Sci 39:617–621. doi:10.​1016/​0024-3205(86)90042-1 CrossRefPubMed
3.
go back to reference Byatt JC, Staten NR, Salsgiver WJ, Kostelc JG, Collier RJ (1993) Stimulation of food intake and weight gain in mature female rats by bovine prolactin and bovine growth hormone. Am J Physiol 264:E986–E992PubMed Byatt JC, Staten NR, Salsgiver WJ, Kostelc JG, Collier RJ (1993) Stimulation of food intake and weight gain in mature female rats by bovine prolactin and bovine growth hormone. Am J Physiol 264:E986–E992PubMed
5.
go back to reference Baptista T, Lacruz A, de Mendoza S, Mendoza Guillén JM, Silvera R, Angeles F, Mendoza MT, Hernández L (2000) Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry 33:81–88. doi:10.1055/s-2000-8451 CrossRefPubMed Baptista T, Lacruz A, de Mendoza S, Mendoza Guillén JM, Silvera R, Angeles F, Mendoza MT, Hernández L (2000) Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry 33:81–88. doi:10.​1055/​s-2000-8451 CrossRefPubMed
6.
go back to reference Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V (2002) Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 147:77–84. doi:10.1530/eje.0.1470077 CrossRefPubMed Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V (2002) Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 147:77–84. doi:10.​1530/​eje.​0.​1470077 CrossRefPubMed
9.
go back to reference Serri O, Beauregard H, Rasio E, Hardy J (1986) Decreased sensitivity to insulin in women with microprolactinomas. Fertil Steril 45:572–574PubMed Serri O, Beauregard H, Rasio E, Hardy J (1986) Decreased sensitivity to insulin in women with microprolactinomas. Fertil Steril 45:572–574PubMed
10.
go back to reference Gustafson AB, Banasiak MF, Kalkhoff RK, Hagen TC, Kim HJ (1980) Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. J Clin Endocrinol Metab 51:242–246CrossRefPubMed Gustafson AB, Banasiak MF, Kalkhoff RK, Hagen TC, Kim HJ (1980) Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. J Clin Endocrinol Metab 51:242–246CrossRefPubMed
11.
go back to reference Schernthaner G, Prager R, Punzengruber C, Luger A (1985) Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 28:138–142PubMed Schernthaner G, Prager R, Punzengruber C, Luger A (1985) Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 28:138–142PubMed
12.
go back to reference Bahceci M, Tuzcu A, Bahceci S, Tuzcu S (2003) Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest 26(7):655–659PubMed Bahceci M, Tuzcu A, Bahceci S, Tuzcu S (2003) Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest 26(7):655–659PubMed
13.
go back to reference Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S (2003) Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 26(4):341–346PubMed Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S (2003) Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 26(4):341–346PubMed
14.
go back to reference Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502PubMed Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502PubMed
15.
go back to reference De Fronzo RA, Tobin JD, Andres R (1979) Glucose clamp tecnique: a method for quantifying insulin secretation and resistance. Am J Physiol 237:E214–E223 De Fronzo RA, Tobin JD, Andres R (1979) Glucose clamp tecnique: a method for quantifying insulin secretation and resistance. Am J Physiol 237:E214–E223
16.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419. doi:10.1007/BF00280883 CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419. doi:10.​1007/​BF00280883 CrossRefPubMed
18.
go back to reference Pelkonen R, Nikkilä EA, Grahne B (1982) Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf) 16:383–390CrossRef Pelkonen R, Nikkilä EA, Grahne B (1982) Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf) 16:383–390CrossRef
19.
go back to reference Foss MC, Paula FJ, Paccola GM, Piccinato CE (1995) Peripheral glucose metabolism in human hyperprolactinemia. Clin Endocrinol (Oxf) 43:721–726CrossRef Foss MC, Paula FJ, Paccola GM, Piccinato CE (1995) Peripheral glucose metabolism in human hyperprolactinemia. Clin Endocrinol (Oxf) 43:721–726CrossRef
21.
go back to reference Serri O, Ling L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366–370 Serri O, Ling L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366–370
22.
go back to reference Cincotta AH, Meier AH, Cincotta M Jr (1999) Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 8(10):1683–1707CrossRefPubMed Cincotta AH, Meier AH, Cincotta M Jr (1999) Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 8(10):1683–1707CrossRefPubMed
23.
go back to reference Baptista T, Lacruz A, Meza T et al (2001) Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry 46:829–834PubMed Baptista T, Lacruz A, Meza T et al (2001) Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry 46:829–834PubMed
24.
go back to reference Creemers LB, Zelissen PM, van’t Verlaat JW, Koppeschaar HP (1991) Prolactinoma and body weight: a retrospective study. Acta Endocrinol (Copenh) 125:392–396 Creemers LB, Zelissen PM, van’t Verlaat JW, Koppeschaar HP (1991) Prolactinoma and body weight: a retrospective study. Acta Endocrinol (Copenh) 125:392–396
25.
go back to reference Kok P, Roelfsema F, Frölich M, Meinders E, Pijl H (2004) Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab 89:4445–4449CrossRefPubMed Kok P, Roelfsema F, Frölich M, Meinders E, Pijl H (2004) Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab 89:4445–4449CrossRefPubMed
26.
go back to reference Schmid C, Goede DL, Hauser RS, Brändle M (2006) Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 138:254–258 Schmid C, Goede DL, Hauser RS, Brändle M (2006) Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 138:254–258
27.
go back to reference Asai-Sato M, Okamoto M, Endo M et al (2006) Hypoadiponectinemmia in lean lactating women: prolactin inhibits adiponectin secretion from human adipocytes. Endocr J 53:555–562CrossRefPubMed Asai-Sato M, Okamoto M, Endo M et al (2006) Hypoadiponectinemmia in lean lactating women: prolactin inhibits adiponectin secretion from human adipocytes. Endocr J 53:555–562CrossRefPubMed
28.
go back to reference Nilsson L, Binart N, Bohlooly YM et al (2005) Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 331:1120–1126CrossRefPubMed Nilsson L, Binart N, Bohlooly YM et al (2005) Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 331:1120–1126CrossRefPubMed
Metadata
Title
Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique
Authors
Alpaslan Tuzcu
Serkan Yalaki
Senay Arikan
Deniz Gokalp
Mithat Bahcec
Sadiye Tuzcu
Publication date
01-12-2009
Publisher
Springer US
Published in
Pituitary / Issue 4/2009
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-009-0183-1

Other articles of this Issue 4/2009

Pituitary 4/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.